You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

Citation Tools

Article menu

This article has a correction. Please see:

Immunotherapy biomarkers
Original research
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lo Russo G, Prelaj A, Dolezal J, et al
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Journal for ImmunoTherapy of Cancer 2023;11:e006833. doi: 10.1136/jitc-2023-006833